Improving the prediction of virological response to tipranavir: The development and validation of a tipranavir-weighted mutation score

Antiviral Therapy

Volumn 15, Issue 7, 2010, Pages 1011-1019

  Schapiro, Jonathan M ^a   Scherer, Joseph ^b   Boucher, Charles A ^c   Baxter, John D ^d   Tilke, Clemens ^e   Perno, Carlo F ^f   Maggiolo, Franco ^g   Santoro, Maria M ^f   Hall, David B ^b  

^a National Hemophilia Center   (Israel)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d Division of Female Pelvic Medicine and Reconstructive Surgery   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; PROTEINASE; RITONAVIR PLUS TIPRANAVIR; TIPRANAVIR;

ADULT; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; SCORING SYSTEM; TIPRANAVIR WEIGHTED MUTATION SCORE; TREATMENT RESPONSE;

ADULT; ANTI-HIV AGENTS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; PYRIDINES; PYRONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; RITONAVIR; VIRAL LOAD;

EID: 78651098695     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1670     Document Type: Article

References (15)

1. Hirsch MS, Gunthard HF, Schapiro JM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285.
2. Vandamme AM, Sönnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9:829-848.
3. United States Department of Health and Human Services Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents 2008. (Updated 1 December 2009. Accessed 21 October 2009.) Available from http://aidsinfo.nih. gov/contentfiles/AdultandAdolescentGL.pdf
4. Vermeiren H, Van Craenenbroeck E, Alen P, et al. Prediction of HIV-1 drug susceptibility phenotype from the viral genotype using linear regression modeling. J Virol Methods 2007; 145:47-55. (Pubitemid 47247892)
5. Parkin N, Chappey C. Protease mutations associated with higher or lower than expected tipranavir (TPV) susceptibility based on the TPV mutation score. 13th Conference on Retroviruses and Opportunistic Infections. 5-8 February 2006, Denver, CO, USA. Poster 637.
6. Baxter JD, Schapiro JM, Boucher CA, et al. Genotypic changes in human immunodeficiency virus type 1 protease associated with reduced susceptibility and virologic response to the protease inhibitor tipranavir. J Virol 2006; 80:10794-10801.
7. Marcelin AG, Masquelier B, Descamps D, et al. Tipranavir-ritonavir genotypic resistance score in protease inhibitorexperienced patients. Antimicrob Agents Chemother 2008; 52:3237-3243.
8. Stanford University HIV Drug Resistance Database. (Updated 24 August 2010. Accessed 15 July 2008.) Available from http://hivdb.stanford.edu/pages/ algs/HIValg.html
9. Van Laethem K, De Luca A, Antinori A, Cingolani A, Perna CF, Vandamme AM. A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients. Antivir Ther 2002; 7:123-129.
10. Rega Institute for Medical Research. Algorithm for the use of genotypic HIV-1 resistance data, Rega v7.1.1©, 5 July 2007. (Updated 10 June 2008. Accessed 15 July 2008.) Available from http://www.rega.kuleuven.be/cev/index. php?id=30
11. Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone and in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008; 47:429-440.
12. Brun-Vézinet F, Costagliola D, Khaled MA, et al. Clinically validated genotype analysis: guiding principles and statistical concerns. Antivir Ther 2004; 9:465-478.
13. Hall DB, Schapiro JM, Boucher CAB, Baxter JD, Piliero P, Scherer J. Development and performance of a trial-specific genotypic sensitivity score based on RESIST data that incorporates treatment history in addition to predicted susceptibility. Reviews in Antiviral Therapy 2008; 2:106.
14. Parkin NT, Chappey C, Petropoulos CJ. Improving lopinavir genotype algorithm through phenotype correlations: novel mutation patterns and amprenavir cross-resistance. AIDS 2003; 17:955-961.
15. Poveda E, de Mendoza C, Parkin N, et al. Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. AIDS 2008; 22:611-616.